Bevacizumab for Malignant Gliomas: Comparative Study with Other Malignancies
Pp. 184-189 (6)
Helen Gu and Thomas C. Chen
Although, the use of temozolomide, as described by Stupp et al. has been hailed as one of the landmark breakthroughs for malignant gliomas, this diagnosis still portends one of the worst prognosis in oncology. Bevacizumab (Avastin) was reported to have favorable results and an acceptable toxicity profile in the treatment of glioblastoma multiforme (GBM) patients who progressed on temozolomide. Given the addition of this potent new treatment agent into the glioma arsenal, and the introduction of a new class of treatment medications it represents; it will be useful to review its clinical history and compare and contrast the experience and pitfalls other oncology sub-specialties have had with this agent.
Dept of Medicine, Oncology (USC) and Dept of Neurosurgery and Pathology (USC).